このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

初経後早期における生殖軸の成熟

初経後初期における生殖軸の成熟:パイロット研究

Background:

Most adult women with irregular periods of unknown cause report symptoms dating back to early adolescence. This study aims to learn how girls' periods change in the 2 years after their first period. We are also looking at girls who may have a condition called PCOS. This will help researchers learn what healthy puberty looks like and how they can spot signs of hormone problems early on.

Objective:

To learn how long it takes girls to develop regular menstrual cycles after their first period.

Eligibility:

Healthy girls ages 8-14 who either (1) haven't had their first period but show signs of puberty, such as breast development and hair in the genital area; or (2) had their first period in the past 6 months

Girls at risk for PCOS age 8-14 who have a mom or sister with PCOS

Girls with irregular menstrual cycles age 11-17.5

To compare with the girls, we are looking at women >=18-34 years old with PCOS,

Healthy women >= 18-34 years old without PCOS,

and Mothers of pediatric participants age 18-65

Design:

Both parents or guardians must allow their daughter to participate. They must attend all study visits with her.

Participants will first be screened by phone. Those who qualify will be screened in person. They will have a physical exam. They will give blood and urine samples. They will have an ultrasound of their abdomen. They will fill out questionnaires. They will sit in a BOD POD for 6 minutes: This is an egg- shaped machine that takes body measurements. They have the option to provide DNA samples.

Participants will have sets of visits at home or at the clinic about every 6 months. The number of visits in each set will depend on their menstrual cycle. Then they will have a final visit. Visits will include repeats of the screening tests. There are additional parts that participants may choose to be involved in depending on how involved they want to be.

At home, participants will collect their urine daily to measure hormones. They will keep a diary of their periods.

Adults: Women with known PCOS will complete the same Screening Visit as the girls and will collect dried urine specimens at home for 8 weeks;

The Healthy control women group will complete the same Screening Visit as the girls and collect dried urine specimens at home for 2 menstrual cycles;

The Mothers of pediatric participants group will complete a Screening Visit (informed consent, urine pregnancy test) and collect vaginal swab specimens at home for 2 menstrual cycles (approx. 8 weeks).

調査の概要

詳細な説明

The broad goal of these studies is to determine the physiologic and pathophysiologic underpinnings of irregular menstrual cycles among adolescents in general and those with increased genetic risk for polycystic ovarian syndrome (PCOS) in the early postmenarchal

period. Irregular menstruation affects > 2.5 million reproductive-age women in the US each year1. Most adult women with oligomenorrhea of unknown etiology reporting symptoms dating back to early adolescence. Importantly, irregular menstrual cycles during the teenage years may be a harbinger of future health risks extending beyond the reproductive system; among the nearly 80,000 female participants the Nurses' Health Study II, those with irregular and long cycles during adolescence and adulthood had a greater risk of premature mortality, particularly related to cardiovascular disease. While a period of cycle irregularity is well-described in the first few years after menarche, a lack of understanding of the basic mechanisms of normal reproductive axis development in the post-menarchal female has hampered our ability to distinguish abnormal from normal developmental trajectories. Moreover, the commonly held belief that menstrual irregularity among teenage girls is normal has also delayed detection of pathology in reproductive development, precluding institution of early preventative strategies to curtail future reproductive morbidity.

研究の種類

観察的

入学 (推定)

400

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

  • 名前:NIEHS Join A Study Recruitment Group
  • 電話番号:(855) 696-4347
  • メール:myniehs@nih.gov

研究連絡先のバックアップ

研究場所

    • North Carolina
      • Research Triangle Park、North Carolina、アメリカ、27709
        • 募集
        • NIEHS Clinical Research Unit (CRU)
        • コンタクト:
          • NIEHS Join A Study Recruitment Group
          • 電話番号:855-696-4347
          • メール:myniehs@nih.gov

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

8年~65年 (子、大人、高齢者)

健康ボランティアの受け入れ

はい

受講資格のある性別

女性

サンプリング方法

非確率サンプル

調査対象母集団

Healthy early post-menarchal girls age 8-<15 years; PCOS women and girls with first degree relatives with PCOS; Healthy women 18-34 years; Late post-menarchal girls age 11-<17.5; healthy pre-menarchal girls age 8-<14.5; mothers of pediatric participants age 18-65

説明

  • Part 1 - Pre-menarche monitoring ("holding pattern"):

Inclusion Criteria:

  • Age 8-14.5 years old
  • Healthy weight, defined as having a body weight >85% of expected (EBW) and a body mass index (BMI) <99th percentile
  • Some breast development
  • Pre-menarche

Exclusion Criteria:

  • Taking or planning to take medications that affect reproductive hormones in the next 2 to 3 years (e.g. birth control pills, biotin supplements).
  • Planning to move more than 60 miles from the CRU within the next 2 to 3 years
  • Chronic medical condition, including but not limited to diabetes mellitus, congenital adrenal hyperplasia, cystic fibrosis, sickle cell disease, inflammatory bowel disease, juvenile rheumatoid arthritis, and lupus.
  • First-degree relative with polycystic ovarian syndrome, premature ovarian insufficiency, hypogonadotropic hypogonadism, or other pubertal development disorder
  • Excessive exercise (defined as running >20 miles per week or its equivalent)
  • Pregnancy

Part 2 - Post-menarche cycle tracking:

Inclusion Criteria:

  • Age at menarche 10-14.5 years old
  • Healthy weight, defined as having a body weight >85% of expected (EBW) and a body mass index (BMI) <99th percentile
  • Approximately < 6 months post-menarchal (will typically have completed 4 or fewer menstrual cycles)
  • Biochemical criteria: normal thyroid hormone, prolactin, and testosterone levels

Exclusion Criteria:

  • Taking or planning to take medications that affect reproductive hormones in the next 2 to 3 years (e.g. birth control pills, biotin supplements).

  • Planning to move more than 60 miles from the CRU within the next 2 to 3 years

  • Chronic medical condition, including but not limited to diabetes mellitus, congenital adrenal hyperplasia, cystic fibrosis, sickle cell disease, inflammatory bowel disease, juvenile rheumatoid arthritis, and lupus.

  • First-degree relative with polycystic ovarian syndrome, premature ovarian insufficiency, hypogonadotropic hypogonadism, or other pubertal development disorder

  • Excessive exercise (defined as running >20 miles per week or its equivalent)

  • Anemia (defined as hemoglobin <12.0 g/dl)

    --Participants with hemoglobin between 11.5 g/dl and 12.0 g/dl may still participate by providing dried blood spots, or no more than 18 ml of blood during any given interval.

  • Pregnancy

Part 3 - Intensive monitoring of ovarian follicle growth

Inclusion Criteria:

  • Age at menarche 10-14.5 years old
  • Healthy weight, defined as having a body weight >85% of expected (EBW) and a body mass index (BMI) <99th percentile
  • Within 1 year of menarche
  • Biochemical criteria: normal thyroid hormone, prolactin, and testosterone levels

Exclusion Criteria:

  • Taking or planning to take medications that affect reproductive hormones in the next 1-2 years (e.g. birth control pills, biotin supplements).

  • Planning to move more than 60 miles from the CRU within the next year

  • Chronic medical condition, including but not limited to diabetes mellitus, congenital adrenal hyperplasia, cystic fibrosis, sickle cell disease, inflammatory bowel disease, juvenile rheumatoid arthritis, and lupus.

  • First-degree relative with polycystic ovarian syndrome, premature ovarian insufficiency, hypogonadotropic hypogonadism, or other pubertal development disorder

  • Excessive exercise (defined as running >20 miles per week or its equivalent)

  • Anemia (defined as hemoglobin <12.0 g/dl)

    --Participants with hemoglobin between 11.5 g/dl and 12.0 g/dl may still participate by providing dried blood spots, or no more than 18 ml of blood during any given interval.

  • Pregnancy

Part 4 - Late Post-menarche cycle tracking:

Inclusion Criteria:

  • Age 11-17.5 years old
  • Approximately 2-5 years post-menarchal
  • Biochemical criteria: normal thyroid hormone and prolactin

Exclusion Criteria:

  • Taking or planning to take medications that affect reproductive hormones in the next 2 to 3 years (e.g. birth control pills, biotin supplements).

  • Planning to move more than 60 miles from the CRU within the next 6 months

  • Chronic medical condition, including but not limited to diabetes mellitus, congenital adrenal hyperplasia, cystic fibrosis, sickle cell disease, inflammatory bowel disease, juvenile rheumatoid arthritis, and lupus.

  • Anemia (defined as hemoglobin <12.0 g/dl)

    --Participants with hemoglobin between 11.5 g/dl and 12.0 g/dl may still participate by providing dried blood spots, or no more than 18 ml of blood during any given interval.

  • Pregnancy

Adolescent girls, at-risk daughters, or sisters of women with PCOS

The girls with mothers or sisters with PCOS group will complete the Screening Visit and Parts 1-3. The same inclusion and exclusion criteria apply for Parts 1, 2, and 3 as stated above except that these individuals must have a first-degree relative with PCOS and they can have high androgen levels, excess body hair, and severe acne at screening.

Women with known PCOS (activities for 8 weeks only)

Inclusion Criteria:

  • Age >=18-34 years old
  • PCOS diagnosis
  • at least 3-years post-menarchal with irregular menstrual cycles
  • Biochemical (blood) or clinical signs of high androgen levels

Exclusion Criteria:

  • Cannot be taking any medications that affect reproductive or metabolic hormones (e.g. birth control pill, biotin supplements, spironolactone, metformin).
  • Chronic medical condition, including but not limited to diabetes mellitus, congenital adrenal hyperplasia, cystic fibrosis, sickle cell disease, inflammatory bowel disease, juvenile rheumatoid arthritis, and lupus.
  • Pregnancy

Healthy control women (Activities for 2 menstrual cycles)

Inclusion Criteria:

  • Age >=18-34 years old
  • at least 3-years post-menarchal with regular menstrual cycles every 21-35 days

Exclusion Criteria:

  • Cannot be taking any medications that affect reproductive or metabolic hormones (e.g. birth control pill, biotin supplements, spironolactone, metformin).
  • Chronic medical condition, including but not limited to diabetes mellitus, congenital adrenal hyperplasia, cystic fibrosis, sickle cell disease, inflammatory bowel disease, juvenile rheumatoid arthritis, and lupus.
  • PCOS diagnosis or first-degree relative with disorder
  • Pregnancy

Mothers of pediatric participants (Activities for 8 weeks / 2 menstrual cycles)

Inclusion Criteria:

  • Age >=18-65 years old
  • Biological mother of A Girl's First Period participant

Exclusion Criteria:

  • Chronic medical condition, including but not limited to diabetes mellitus, congenital adrenal hyperplasia, cystic fibrosis, sickle cell disease, inflammatory bowel disease, juvenile rheumatoid arthritis, and lupus.
  • Pregnancy

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 観測モデル:COHORT
  • 時間の展望:PROSPECTIVE

コホートと介入

グループ/コホート
At-risk girls

Girls with first degree relative diagnosed with Polycystic Ovary Syndrome (PCOS) age 8-<15

early post-menarche girls

Healthy, early post-menarchal girls age 8-<15

Healthy control women

Women age >18-34 without PCOS at least 3-years post-menarchal with regular menstrual cycles every 21-35 days

late post-menarche girls

Late post-menarchal girls age 11-<17.5 (gynecological age 2-5)

Mothers of pediatric study participants

Mothers age 18-65 whose daughter has provided at least one vaginal swab sample for the First Period study.

pre-menarche girls

Healthy, pre-menarchal girls age 8-<14.5

Women with PCOS

Women diagnosed with PCOS >18-34 at least 3-years post-menarchal with irregular menstrual cycles

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
To determine the time from menarche to regular ovulatory cycles, defined as two consecutive ovulatory cycles in girls of variable genetic risk for PCOS
時間枠:Defined as two consecutive ovulatory cycles with normal (10-14 day) luteal phase length during the first two post-menarchal years

We hypothesize that the temporal sequence of reproductive maturation will consist of anovulatory cycles (representing a time of unopposed estrogen exposure), ovulatory cycles with a short luteal phase (estrogen with low progesterone exposure), and finally, ovulatory cycles with a normal luteal phase length (estrogen action fully counterbalanced by progesterone action)

Defined as two consecutive ovulatory cycles with normal (10-14 day) luteal phase length during the first two post-menarchal years

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • 主任研究者:Natalie D Shaw, M.D.、National Institute of Environmental Health Sciences (NIEHS)

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2019年12月19日

一次修了 (推定)

2029年7月1日

研究の完了 (推定)

2029年7月1日

試験登録日

最初に提出

2019年6月13日

QC基準を満たした最初の提出物

2019年6月13日

最初の投稿 (実際)

2019年6月14日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月5日

QC基準を満たした最後の更新が送信されました

2026年11月4日

最終確認日

2026年11月3日

詳しくは

本研究に関する用語

その他の研究ID番号

  • 190110
  • 19-E-0110

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

未定

IPD プランの説明

It is not yet known if there will be a plan to make IPD available

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する